Proliferative activity of antigen-specific CD154+ T cells against bacterial and fungal respiratory pathogens in cystic fibrosis decreases after initiation of highly effective CFTR modulator therapy
Background: Together with impaired mucociliary clearance, lung disease in cystic fibrosis (CF) is driven by dysregulation of innate and adaptive immunity caused by dysfunctional CFTR (Cystic Fibrosis Transmembrane Conductance Regulator), leading to airway infection and hyperinflamma-tion. The highly...
Saved in:
Main Authors: | Patience N. Eschenhagen (Author), Petra Bacher (Author), Claudia Grehn (Author), Jochen G. Mainz (Author), Alexander Scheffold (Author), Carsten Schwarz (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antibiotic Therapy for Pulmonary Exacerbations in Cystic Fibrosis-A Single-Centre Prospective Observational Study
by: Carsten Schwarz, et al.
Published: (2023) -
Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score
by: Jochen G. Mainz, et al.
Published: (2022) -
Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score
by: Jochen G. Mainz, et al.
Published: (2023) -
Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire
by: Jochen G. Mainz, et al.
Published: (2023) -
Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis
by: Patrick O. Hanafin, et al.
Published: (2021)